Genmab announces positive results for sclerosis drug candidate

COPENHAGEN (Reuters) - Danish biotech firm Genmab on Thursday announced positive results from a phase II study of its sclerosis drug candidate ofatumumab. In a randomised study of 232 patients with relapsing-remitting multiple sclerosis, treatment with ofatumumab significantly reduced the cumulative number of new brain lesions, the company said. Relapsing-remitting multiple sclerosis is the most common form of multiple sclerosis, which is an inflammatory disease of the central nervous system. ...



via Health News Headlines - Yahoo! News http://news.yahoo.com/genmab-announces-positive-results-sclerosis-drug-candidate-200748374--finance.html